Nitric oxide (NO) production plays a central role in conferring tolerance to hypoxia.
INTRODUCTION
The partial pressure of oxygen decreases on ascent to high altitude as a result of a decline in barometric pressure; at 5300m (the height of Everest base camp) it is approximately half the value at sea level. (1) This hypobaric hypoxia causes hypoxaemia (a lack of oxygen in the blood) resulting in significant physiological challenges. The respiratory system is particularly affected, and consequently respiratory problems make up some of the most common (e.g. high altitude cough) and also the most serious (e.g. high altitude pulmonary oedema or HAPE) illnesses encountered at high altitude.(2) Respiratory pathologies and hypoxaemia are also commonly encountered in critical care patients but are very difficult to study in this setting. High altitude environments might therefore provide a model for pathological hypoxaemia from which much can be learned. (3) Interestingly, native lowlanders appear to respond to acute hypobaric hypoxia differently from native highlanders (i.e. populations permanently residing above 3000m). For example, native lowlanders seem to rely heavily on increased erythropoiesis to maintain oxygen content at altitude,(1) whilst this response is much less pronounced in native highlanders such as the Sherpas (supremely adapted after living at high altitude for over 500 generations).(4) Another notable difference that is remarkably conserved across different high altitude populations (including the Tibetan populations and the Bolivian Aymara) is that mountain dwellers exhale higher concentrations of nitric oxide (NO) compared to individuals living at sea level. (5, 6) However, exhaled NO levels decrease significantly in lowland populations on acute exposure to altitude.(7) During graded exposure to altitude, however, NO production increases also in lowlanders suggesting that NO production and particularly respiratory NO availability might play an important role in offsetting the effect of hypoxia and improve performance. (8) NO is a ubiquitous signalling and effector molecule, and an important modulator of oxygen delivery through effects on blood pressure and blood flow as well as mitochondrial respiration. As well as these vasoactive properties, it also plays crucial roles in inflammation (including pulmonary and airway inflammation) and in the immune system, as a cytotoxic entity and by abating oxidative stress. (9) Moreover, in hypoxia it plays a key role in energy supply-demand matching. (10) Inhaled NO has been shown to reduce pulmonary artery pressures and increase arterial oxygenation in critical care patients suffering from Acute Respiratory Distress Syndrome by improving ventilation-perfusion matching. (11) Inhaled NO has also been used to treat patients suffering from HAPE, successfully reducing oedema and increasing arterial oxygenation. (12) NO is produced through two main pathways in the body, both regulated by oxygen. While the enzymatic formation of NO from L-arginine by nitric oxide synthases (NOS) is an oxygen-requiring process, production of NO through serial reduction of inorganic nitrate (NO 3 -) to nitrite (NO 2 -) and NO is inhibited by oxygen. (13) It is this second mechanism that is thought to underlie the significant increase in markers of NO metabolism observed in acclimatizing lowlanders and also well-adapted Sherpas at high altitude. (8) Dietary nitrate is initially reduced to nitrite by the oral bacterial flora in the mouth, before nitrite can be further reduced to NO in the acidic environment of the stomach and in vascular tissue by various nitrite reductase enzymes. (14) (15) (16) Besides its use as an ergogenic aid in sports medicine, (17) (18) (19) (20) (21) attempts to increase nitrate intake through dietary supplements have also been trialled as therapeutic interventions in respiratory patients suffering from chronic obstructive pulmonary disease (COPD), which results in a chronic hypoxaemic state, with mixed results. (22) (23) (24) (25) (26) ) Some studies showed beneficial effects such as increased exercise performance and lower resting blood pressure, (22, 24) whilst other studies did not
show any significant improvements in exercise performance.(25,26) Some studies only showed limited improvements (such as reduced oxygen consumption) but suggested that these benefits might be greatest in the most hypoxic patients. (23) However, all of these studies demonstrated that dietary nitrate supplementation is both safe and tolerable to patients. If dietary nitrate supplementation could improve physiological performance under other hypoxic conditions then it could potentially be an effective and economic treatment for hypoxaemia in critically ill patients.
The Xtreme Alps expedition was a double-blinded randomised placebocontrolled trial designed to investigate how dietary nitrate supplementation affects performance at altitude.(27) This report focuses on the findings of the study's respiratory outcomes, baseline observations and acute mountain sickness (AMS) scores.
METHODS

Study setting and participants
Details of the Xtreme Alps expedition and protocols have been previously described.(27) A total of 28 healthy adult volunteers (aged 21-40 years) were recruited after completing a health screening process to identify those at risk of problems at high altitude (as detailed in (27)). Of these, 21 (75%) were male. The mean weight was 73.3 kg (± 11.6), mean height 1.76 m (± 0.08), and mean BMI 23.6
(± 2.7). 3.6% were smokers and 75% had previously been to an altitude of over 3000m. Anyone deemed unfit to undergo a formal exercise test at high altitude (as previously described (28) Figure 1A ) before descending on foot again. This schedule included a planned rest day on arrival at 4559m for each group (during which the first group could build and set up the laboratory), followed by 5 days of testing. In the laboratory at 4559m, the mean barometric pressure, temperature and partial pressure of oxygen were 78.1kPa, 22.6°C and 15.1kPa respectively.
Randomisation
Following enrolment, participants were randomly allocated to receive either a high nitrate supplement (intervention group) or low nitrate supplement (placebo group) in accordance with the CONSORT 2010 guidelines (http://www.consortstatement. org/) and accounting for the need for equal numbers of individuals in both groups whilst maintaining gender distribution. Both participants and investigators were blinded to group allocations for the duration of the study, including the analysis of the primary data sets.
Intervention
The intervention juice was a custom formulated all-natural beetroot/fruit juice blend (produced, pasteurised and packaged into 200 mL food-grade aluminum foil pouches individually labelled with anonymized subject codes by Aurapa GmbH, Bietigheim-Bissingen, Germany). The total daily nitrate dose targeted by the high nitrate intervention was similar to that shown by others to be effective in improving exercise performance at sea level (range 0.10-0.18 mmol/kg/day),(29,30) and divided into three individual doses for consumption in the morning, at midday and in the evening. The low-nitrate (placebo) version was produced in the same manner using beetroot juice in which the majority of nitrate had been removed by selective microbial denitrification. Administration, both at sea level and high altitude, commenced 72 hours prior to the start of and continued throughout each testing period. However, as all subjects in both the placebo and treatment groups were taking beetroot juice for 3 days prior to each experimental period starting, we were unable to measure baseline (or 'treatment-free' control) measurements either at sea level or at altitude in either of these groups. A limited amount of data is available for E NO and breath condensate levels from treatment-naïve members of the laboratory team, who did not receive any supplement as they were not part of the main study;
this data is presented where available on the appropriate figures. However, the error bars for this group are large as the n-values are small and often variable (not all individuals were always available and some unwell, requiring medication and/or experiencing respiratory inflammation on certain days) -these individuals were never intended to be part of the main study but presented here for comparison to the placebo group. All meals consumed by subjects during the study period were standardised in order to minimise nutritional nitrate intake.
Daily diary, measuring observations & AMS scores
All participants completed a daily diary first thing each morning before any oral intake (including food, caffeine, placebo or intervention supplements). Peripheral oxygen saturation (SpO 2 ), heart rate (HR), respiratory rate (RR) and blood pressure For each measurement subjects inspired to total lung capacity before slowly expiring against a defined resistance to ensure proper velum closure. During expiration an electronic visual display helped each subject maintain a steady flow of 50 ml/s in accordance with ATS guidelines -a smiley face against a green background was displayed when the ultrasonically measured flow was within limits (50 ml/s ±5%), with red warning signs flashing when the flow fell below the minimum or exceeded the maximum level. A minimum of 3 successful repeats with stable flow rates for at least 6 second were collected for each measurement.
Measures of nitric oxide/nitrate metabolites
Samples of unstimulated saliva were collected using dedicated collection NO metabolite concentrations were quantified using reductive gas-phase chemiluminescence (for determination of total nitrosation products, RXNO) and HPLC (for nitrite and nitrate), as described elsewhere (8) . 
Analysis plan
RESULTS
Dietary nitrate intake and supplementation
The nitrate concentration of the placebo supplement was 1.4 (±0.1) mM; Combined, the placebo group received an average of 29.5 µmol nitrate/kg bw per day, slightly (20%) above the average UK intake whilst the intervention group received up to 186 µmol nitrate/kg bw per day, or 6.6 times larger than the normal UK daily intake with minimal addition of nitrite from either placebo or intervention to the diet.
Baseline physiological observations
Increasing exposure to hypobaric hypoxia at high altitude produced marked changes in participants' resting physiological variables (see Figure 1 ). Resting SpO 2 initially decreased with each incremental rise in altitude, before stabilising as further time was spent at each elevation (see Figure 1B) . Meanwhile, resting respiration rates (RR) initially increased on ascent before trending back towards baseline values (see Figure 1C ). Mean resting SpO 2 at sea level was 98.3% (±1.1) and 97.7% (±1.5) for Trek 1 and 2 respectively, decreasing to 77.3% (±8.0) and 81.1% (±6.84) on their first day at 4,559m (day 3 and day 4, respectively). Mean RRs for Trek 1 and 2 respectively were 10.6 (±2.9) and 11.8 (±2.6) at sea level, increasing to 16.1 (±5.7) and 14.2 (±4.0) at arriving at 4,559m, and decreasing to 12.3 (±3.1) and 11.9 (±3.1) by day 10. A similar response pattern was also seen for resting heart rate and blood pressure ( Fig. 1D & 1E ). All physiological trends were similar between both ascent profiles; hence all other measurements were pooled for subsequent analysis.
Acute Mountain Sickness (AMS)
There was no significant difference in the incidence of Acute Mountain Sickness (AMS) between the intervention and placebo groups, p = 0.29 (see Figure 2) . Similarly, the dietary nitrate supplement did not significantly alter the incidence of headache at altitude (p = 0.47). Both of these findings remained consistent when the different ascent rate (different trek groups) was also included in the linear-regression model. One subject was evacuated hours after arriving at 4559m after developing high altitude cerebral oedema (HACE). No one developed HAPE.
Lung function, exhaled NO and NO metabolite levels in exhaled breath condensate
All sea level spirometry variables were normally distributed. All subjects (2 in the treatment group smoked) had normal lung function and there was no significant difference seen between the placebo and treatment groups for any sea level spirometry variable when tested (see Table 1 ).
All measured breathing and salivary variables were normally distributed after log transformation. As shown in Table 2 , Table 4 and Figure 3 nitrate supplementation and hypobaric exposure both robustly increased E NO levels, and this result remained significant after adjusting for multiple comparisons. Nitrate supplementation also significantly increased nitrite concentrations in EBC.
When modeled for days spent at altitude, dietary nitrate supplementation significantly increased E NO levels (p=0.02), with median values from 1.5 mPA (IQR 
Oral nitrate reduction and NO metabolite levels in saliva
Similar to EBC, salivary NO metabolite levels at sea level and high altitude varied considerably between individuals. Dietary nitrate supplementation significantly increased salivary levels of nitrate (p < 0.001), nitrite (p < 0.001) and RXNO (p = 0.04) (see Table 3 and A secondary sensitivity analysis did not alter the significance of any of these results. However, despite significant increases in all of these biochemical markers of NO availability, there was no identifiable difference between the intervention and placebo group in any resting physiological variable or score of AMS severity (see Figure 2 ).
Discussion
The novelty of the present study is that it was performed under field conditions (rather than at simulated altitude in a hypobaric chamber) with mountaineer subjects residing at altitude over a prolonged period of time. This experimental design allowed us to take serial measurements in order to examine how dietary nitrate supplementation (ingested in three equal doses throughout each day) affects physiological acclimatization to altitude.
Main findings -Exhaled NO (E NO )
These results demonstrate that dietary nitrate supplementation with a beetroot/fruit juice mixture at altitude successfully increases nitrate availability; these increases are Growing evidence supports the notion that both NO and nitrate metabolism play important roles in the physiological response to hypoxia, and also the benefits that nitrate supplementation can confer on individuals' physiological performance. (10, 41) However, the physiological role of E NO specifically in either of these situations is unclear, and clinically the measurement of Fe NO has mainly been as a point-of-care test for airway inflammation in patients with asthma. (42) Its association with the development of AMS is much less certain.
While it has been suggested that E NO may be associated with AMS, this is not without controversy. One of those studies that led to this conclusion was performed in a hypoxic chamber and subjects only experienced 6 hours of exposure to a normobaric hypoxic stimulus. (43) 
Exhaled breath condensate (EBC) results
EBC is being increasingly used to detect levels of airway inflammation, monitor disease progression and also assess disease severity in a number of respiratory conditions including adults and children with atopic asthma. (48, 49) However, despite offering a relatively cheap, quick, simple and non-invasive window into lung physiology, its usefulness in altitude-related respiratory illnesses is less explored.
There is some evidence to suggest EBC could be useful in predicting altituderelated illness. Results from a small study (5 subjects + 11 controls) suggested that EBC analysis before and after 90 minutes of normobaric hypoxic (12% oxygen) exposure might be able to distinguish between individuals with and without a history of HAPE. (50) Meanwhile, another study demonstrated that EBC measurements conducted at 670m and 3000m of malondialdehyde (MDA), a marker of oxidative stress, significantly correlated with the AMS scores of 10 soldiers at 5000m as they ascended a 6125m peak. (51) Other oxidative stress markers (e.g. 8-iso prostaglandin F2α) have also been shown to significantly increase in EBC measurements in small numbers of both exercising biathletes (n=10) and sedentary volunteers (n=5) over a six week period at 2800m, further supporting our findings presented here. (52) In a study similar to ours also making EBC measurements at 4342m from seven subjects receiving dietary L-arginine supplementation -an intervention that should increase endogenous NO production via the classical nitric oxide synthase pathway -no improvement in AMS scores were seen with supplementation. In fact, this study found that the treatment group actually developed significantly worse headaches. (53) Again, the biggest difference between all of these previous studies and the results we present here is the scale of the study. To the best of our knowledge, the Xtreme Alps expedition is currently the largest study and 4559m is also the highest altitude at which EBC samples have yet been collected. While no association was found between NO metabolite related changes in EBC and AMS in the present study, future well-powered studies are needed to determine whether or not this technique could help predict or diagnose altitude illness using other biomarkers.
A curious finding was that nitrite and nitrate concentrations in EBC measured in the present study were almost identical. This is unlike any other compartment where nitrate levels are typically exceeding nitrite levels by at least an order of magnitude. Moreover, we found that dietary nitrate resulted in significant rises to levels of EBC nitrite -with almost identical rises seen both at sea level and at altitude -but almost no difference to EBC nitrate. This strongly suggests that both EBC nitrate and nitrite are under active regulatory control, even when the exact mechanisms of sensing and regulation remain unclear. We also noted moderate associations between levels of EBC nitrite and Fe NO , even in the low nitrate/placebo group and particularly at altitude. We believe that, for the first time, this provides evidence to suggest that nitrite in airway secretions might be acting as a possible source of E NO . Whether or not these observations are of further biological significance warrants further investigation.
Enterosalivary nitrate circulation
The 
Dietary nitrate and altitude illness
Our findings suggest that even though dietary nitrate supplementation at altitude results in increased biochemical nitrate availability, this does not improve acclimatization and/or reduce the incidence of AMS. Another hypobaric chamber study recently showed similar increases in E NO after just a single dose of sodium nitrate. However, despite E NO increasing by 24% at a simulated altitude of 4300m, there was no demonstrable benefit in isometric exercise performance, forearm blood flow or tissue oxygenation.(39) Meanwhile another study, which recently exposed 20 healthy volunteers to 6 hours of 12% oxygen in a normobaric chamber, actually
showed an increase in AMS scores (particularly headache) with dietary nitrate, contrasting our findings.(61) Inhaled NO has previously been shown to reduce pulmonary arterial pressures both at sea level and at altitude, offering particular benefit to HAPE-susceptible patients who tend to have high pulmonary artery pressures. (11, 12) One explanation of these findings perhaps is that even a mild vasodilatory effect on the pulmonary vasculature confers benefits at altitude, particularly in people with naturally high pulmonary artery pressures. Meanwhile any cerebrovascular dilation in patients results in increased cerebrovascular flow and worsening of headache symptoms, particularly in those most susceptible to AMS.
Strengths and limitations
The Xtreme Alps study is one of the earliest double-blinded randomised placebo control trials of dietary nitrate supplementation at altitude that the authors are aware of, and also one of the larger studies to investigate the effects of nitrate metabolism at altitude. Nevertheless, absolute numbers remain rather moderate in each arm of the trial; we also had a number of missing data points due to subjects not being able to participate on some test days, usually due to altitude related illness. Consequently, confidence intervals remained wide in all reported measures so we cannot completely exclude a type-2 error, although a sensitivity analysis to correct for these missing values did not change these outcomes.
Since the Xtreme Alps study was conducted, other studies have emerged that also investigated how nitrate supplementation may affect performance at altitude, however most have used a simulated (chamber) altitude environment. In accordance with our findings, AMS incidence was shown to be similar to controls in cyclists taking dietary nitrate supplements exposed to short sessions of 11% oxygen in a normobaric chamber. (62) clear. However, all of these results were in response to a very different physiological stimulus to the intervention presented here. Our subjects were exposed to hypobaric hypoxia gradually over a number of days; in chamber studies subjects tend to experience a much shorter duration and more rapidly induced period of normobaric hypoxia. For example, in one normobaric chamber study reporting an increase in cycling performance after just one dose of nitrate, subjects were decompressed to 15% oxygen in just 5 minutes.(64) Equally, the physiological response to normobaric and hypobaric hypoxia may not be the same, as suggested by a recent systematic review. (67) Currently Xtreme Alps remains the largest field study to date to explore the effects of dietary nitrate by taking serial measurements over a prolonged duration of hypobaric hypoxic exposure at high altitude.
Another study strength was the fact that the supplement we used to deliver nitrate (a natural beetroot/fruit juice blend) was almost identical in taste, appearance and composition to the placebo (the same mixture except that the beetroot/fruit juice was selectively reduced in nitrate). Ours is the only study we are aware of that also monitored nitrite and nitrate intake with the food.
As alluded to before, ascent occurred in two successive phases but inclement weather conditions meant that these ascent profiles could not be identical. However, statistical modeling has allowed us to control for these differences in ascent profile as much as possible, and trends between both ascent groups were similar. With each subject starting their beetroot juice supplement (containing either high nitrate 'treatment' or very low nitrate 'placebo') three days prior to each testing period, this meant we were unable to record baseline values at either sea level or at altitude. We were also unable to take a complete third 'treatment free' control group to altitude without reducing the power of the study due to the space available at 4559m.
However, the few measurements that were taken on the small number of treatment free laboratory team members all closely matched those of the placebo group suggesting that the low nitrate placebo supplement taken by this group did indeed behave as a placebo agent.
The majority of our subjects were young, non-smoking males with previous altitude experience, which is unsurprising given we primarily recruited from a mailing list of medical scientists and healthcare workers with an interest in high-altitude travel and hypoxia physiology. Panel 1A -ascent profile, 1B -resting oxygen saturation per expedition day, 1C -resting respiration rate, 1D -resting heart rate, and 1E -resting blood pressure (systolic over diastolic). Representative results of the daily diary morning routine recording resting vital signs and symptoms of Acute Mountain Sickness (AMS). No significant difference was seen between the low nitrate group (placebo) and the high nitrate group (intervention) in peripheral oxygen saturation (SpO 2 ), respiratory rate, heart rate, systolic blood pressure, diastolic blood pressure or Lake Louise Score (for AMS) on testing at sea level in London (75m), on participants' first day at 3611m or on the first testing day at 4559m (D1 in Figure 1 ). 
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